booster doses – Page 3 – Communicable Diseases Research

Advances in the Omicron variant development

Omicron 변종 개발의 발전

Review

Published on 2022-07-012022-09-11
Journal: Journal of internal medicine [Category] COVID19(2023년), SARS, 변종, 진단, 치료제,

COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study

COVID-19 백신 약화 및 부스터의 효과 및 부작용: ZOE COVID 연구의 전향적 커뮤니티 연구

Article

Published on 2022-07-012022-09-11
Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 변종,

[키워드] 95% CI Adverse reaction Adverse reactions Alpha Analysis B.1.1.7 BNT162b2 booster booster dose booster doses ChAdOx1 ChAdOx1 nCoV-19 chronic chronic disease Community community setting Comorbidities completion confounder confounders Control country COVID COVID-19 COVID-19 vaccine dose effective Effectiveness fatigue foundation group Heterologous heterologous schedule heterologous schedules homologous schedule individual Infection investigated Local local symptom Medical Research Council mRNA mRNA-1273 mRNA1273 nCoV new SARS-CoV-2 Odds ratio Older participant Participants Pfizer-BioNTech Poisson regression model positive reactogenicity receiving regimens remained reported SARS-CoV-2 SARS-CoV-2 positivity SARS-CoV-2 test second dose self-reported systemic Side-effect Side-effects Symptom systemic systemic side-effect Systemic side-effects systemic symptom tenderness test result tested those with comorbidities vaccinated individual vaccinated individuals vaccination Vaccine vaccine dose variant variants waned Wellcome Trust
[DOI] 10.1016/S1473-3099(22)00146-3 PMC 바로가기 [Article Type] Article

Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan

대만의 건강한 성인에서 동종 및 이종 ChAdOx1-S 및 mRNA-1273 백신 접종의 면역원성과 안전성

Article

Published on 2022-06-012022-09-12
Journal: Journal of Clinical Virology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] Abbott Diagnostics age antibody production Antibody Response Antibody titer booster doses ChAdOx1-S collected COVID-19 COVID-19 vaccine COVID-19 vaccines cPass™ detection division Elecsys® Anti-SARS-CoV-2 S Genscript Germany healthy Heterologous heterologous prime-boost homologous Homologous and heterologous prime-boost regimens homologous or heterologous humoral immune response IgG immunogenicity induce Ireland Moderna mRNA-1273 Neutralizing New Participants priming regimen robust Roche Diagnostics Safe Safety safety profile SARS-CoV-2 SARS-CoV-2 IgG serum sample shown Sligo Taiwan USA vaccination Vaccine were given were measured
[DOI] 10.1016/j.jcv.2022.105156 PMC 바로가기 [Article Type] Article

Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2

SARS-CoV-2의 우려 변종에 대한 BBIBP-CORV 백신의 추가 용량의 면역 반응

Observational Study

Published on 2022-06-012022-09-11
Journal: Journal of Clinical Virology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단,

[키워드] (alpha Alpha Antibody titer Antibody titers approved BBIBP-CorV Beta booster booster dose booster doses Cohort COVID-19 COVID-19 vaccination COVID-19 vaccinations dose doses Evidence fold immune response inactivated Inactivated vaccine Inactivated Vaccines inactive individual Lineage lineages neutralization test Neutralizing antibodies Neutralizing antibody titer neutralizing antibody titers neutralizing effect observational study offered plaque pooled serum primary dose primary doses PRNT recipient recipients reduction reduction in sample pool SARS-CoV-2 SARS-CoV-2 variants serum serum sample serum samples statistically significant Test the SARS-CoV-2 Vaccinations Vaccine vaccine cohort variant variants variants of concern was done Wuhan
[DOI] 10.1016/j.jcv.2022.105161 PMC 바로가기 [Article Type] Observational Study

Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic

SARS-CoV-2 오미크론(B.1.1.529) 변종, 두드러진 특징, 높은 전 세계 건강 문제 및 진행중인 COVID-19 대유행 속에서 이에 대응하기 위한 전략의 출현

Review

Published on 2022-06-012022-09-11
Journal: Environmental research [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 진단,

[키워드] accumulation Alpha Analysis animals appearance approach B.1.1.529 Beta booster doses China COVID-19 pandemic Delta Delta variants Diagnosis Efficacy emergence evade Evolution explain Features Gamma generate Genome genome analysis Health humans Immune escape immune pressure Immunity immunotherapies Immunotherapy implementation Infection late less lethality long term measure multivalent vaccine mutated Mutation mutation rate Mutation rates natural infection omicron Omicron origin patients persistence pre-existing immunity prevention Prevention and control raising receiving SARS-CoV-2 SARS-CoV-2 pandemic Spike protein the spike protein Therapies vaccination Vaccine Vaccine failure Vaccines variant variant of concern variants virus VoC
[DOI] 10.1016/j.envres.2022.112816 PMC 바로가기 [Article Type] Review

Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study

델타 변이체(B.1.617.2) 및 스코틀랜드 환자의 2차 접종 이후 경과 시간(REACT-SCOT)과 관련된 중증 COVID-19에 대한 백신 효능: 사례-대조군 연구

Article

Published on 2022-06-012022-09-11
Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘,

[키워드] 95% CI age Alpha Analysis ascertainment bias B.1.1.7 B.1.617.2 booster doses Case-control case-control study ChAdOx1 ChAdOx1 vaccine classification coded community health Control controls COVID-19 Critical care database death declined decrease defined delta variant diagnosed dose Efficacy expected first positive Follow-up hospitalisation include index measure Moderna mRNA mRNA vaccine mRNA vaccines not limited outcome Patient Pfizer predominant presenting primary care primary outcome measure Protective replaced replacement report reported reversed risk SARS-CoV-2 variant Scottish second dose selected Severe case severe cases severe COVID-19 severe disease severity Sex study period suggested Support transmission rate transmission rates vaccination Vaccine vaccine efficacy Vaccines variant
[DOI] 10.1016/S2213-2600(22)00045-5 PMC 바로가기 [Article Type] Article

Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections

SARS-CoV-2-나이브 및 -경험 대상자에서 BNT162b2 mRNA 백신에 대한 세포 및 체액 면역 반응의 동역학 및 지속성: 추가 용량 및 돌발 감염의 영향

Article

Published on 2022-05-312022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료법,

[키워드] administration age analyzed Anti-nucleocapsid antibodies anti-SARS-CoV-2 anti-spike antibodies anti-spike antibody antibodies antibody association Belgium benefit blood sample Blood samples blood sampling BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine booster booster dose booster doses breakthrough infections cell-mediated immune response cellular cellular and humoral immune response Cellular immune response cellular immune responses collected COVID-19 COVID-19 vaccine DiaSorin dose Elecsy enrolled evaluated greater HCW HCWs Healthcare system healthcare worker Healthcare workers help Human humoral Humoral and cellular immune responses humoral immune response Humoral response IFN-γ IgG immune protection immune response immune responses immunization immunogenicity Impact implication increase in individual level individuals Infection initial Kinetics LIAISON Lymphocytes management mandatory mRNA vaccination mRNA vaccine naïve naïve individuals natural infection Neutralization assay neutralization capacity Neutralizing antibodies pandemic participant Participants Peripheral blood peripheral blood lymphocyte peripheral blood lymphocytes persistence Prevent Prospective Study Qiagen QuantiFERON quantified reduce regimen response SARS- CoV-2 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination second dose secretion severe COVID-19 significantly higher tested the SARS-CoV-2 triggering understanding university vaccination vaccine dose variant Vero E6 was performed
[DOI] 10.3389/fimmu.2022.863554 PMC 바로가기 [Article Type] Article

Time trends in social contacts of individuals according to comorbidity and vaccination status, before and during the COVID-19 pandemic

COVID-19 대유행 전과 동안, 동반이환 및 예방접종 상태에 따른 개인의 사회적 접촉의 시간 경향

Article

Published on 2022-05-232022-09-11
Journal: BMC Medicine [Category] COVID19(2023년), SARS, 변종,

[키워드] 95%CI analyses Analysis booster dose booster doses Canada Christma Comorbidities Comorbidity Complication conducted Contact COVID-19 COVID-19 complications COVID-19 pandemic COVID-19 vaccination cross-sectional described distance Efficacy explained first dose First wave Generalized linear model greater Immune escape individual Infectious diseases Intervention masking medical condition medication MONITOR outcome pandemic participant performed physical contact Poisson distribution Public public health Quebec, Canada questionnaire random recruited repeated risk of COVID-19 robust second wave significant difference significantly social contact Social contacts the mean the vaccine time used data vaccination Vaccination Status Vaccine vaccine efficacy variant
[DOI] 10.1186/s12916-022-02398-x PMC 바로가기 [Article Type] Article

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar

카타르에서 SARS-CoV-2 오미크론 감염에 대한 mRNA 백신 부스터의 효과

Article

Published on 2022-05-122022-09-11
Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 변종, 진단, 치료법,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 association B.1.1.529 B.1.617.2 BNT162b2 booster booster dose booster doses booster vaccination Cohort cohorts conducted coronavirus coronavirus disease Coronavirus disease 2019 cumulative cumulative incidence death dose Effect effective Effectiveness effort Follow-up Hospitalization incidence Infection less Messenger RNA Moderna mRNA mRNA-1273 mRNA-1273 vaccine of BNT162b2 omicron Pfizer-BioNTech protection regression models retrospective cohort study SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus symptomatic symptomatic infection symptomatic SARS-CoV-2 infection Vaccine variant variants with infection
[DOI] 10.1056/NEJMoa2200797 PMC 바로가기 [Article Type] Article

Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine

AstraZeneca COVID-19 백신의 위험 대비 이점을 추정하기 위한 증거 기반 베이지안 네트워크 설계

Article

Published on 2022-05-112022-09-11
Journal: Vaccine [Category] 변종,

[키워드] Adverse adverse events age AstraZeneca Atypical AZ vaccine Bayesian Bayesian network benefit blood clot Blood clots booster doses can be used Clinicians community transmission Comorbidities Comorbidity contribute COVID COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines determine Evidence expand expert for inclusion generate Government groups Health include individuals Informed Informed decision-making International Local methodology Model outcome outcomes provide researcher risk Sex These data thrombocytopenia thrombosis Uncertainty vaccination Vaccine hesitancy variables variant virus was used were used
[DOI] 10.1016/j.vaccine.2022.04.004 PMC 바로가기 [Article Type] Article